A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Mild Cognitive ImpairmentDementia
Interventions
DRUG

ladostigil hemitartrate

10mg ladostigil base administered once daily as hard gelatin capsule

DRUG

Placebo

Placebo comparator

Trial Locations (12)

1130

Privatordination Rainer, Vienna

6060

Landeskrankenhaus Hall, Memory Klinik, Hall in Tirol

8036

Medizinische Universitat Graz, Abteilung fur Neurologie, Graz

13088

Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH, Berlin

26655

Studienzentrum Nordwest, Westerstede

30120

Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische, Magdeburg

31096

Cognitive Neurology Unit, Rambam Health Care Campus, Haifa

34362

Cognitive Clinic, Department of Geriatrics, Carmel Medical Center, Haifa

52621

Memory Clinic, Sheba Medical Center at Tel Hashomer, Ramat Gan

64239

Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center, Tel Aviv

84170

Department of Geriatrics and Memory Clinic, Mental Health Center, Israel, Beersheva

91240

Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035, Jerusalem

Sponsors
All Listed Sponsors
lead

Avraham Pharmaceuticals Ltd

INDUSTRY

NCT01429623 - A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter